Thrombocytopenia represents a risk for deterioration of liver function after radiofrequency ablation in patients with hepatocellular carcinoma

• Main Authors: Hyun Seok Lee, Soo Young Park, Sung Kook Kim, Young Oh Kweon, Won Young Tak, Chang Min Cho, Seong Woo Jeon, Min Kyu Jung, Hyun Gu Park, Dong Wook Lee, So Young Choi
• Format: Article
• Language: English
• Published: Korean Association for the Study of the Liver 2012-09-01
• Series: Clinical and Molecular Hepatology
• Subjects: Radiofrequency ablation; Thrombocytopenia, Liver function
• Online Access: http://e-cmh.org/upload/pdf/cmh-18-302.pdf
• ISSN: 2287-2728; 2287-285X

Background/AimsWe evaluated changes in liver function parameters and risk factors for the deterioration of liver function 12 months after percutaneous radiofrequency ablation (RFA) therapy in patients with hepatocellular carcinoma (HCC).MethodsThe subjects in this retrospective study comprised 102 patients with HCC who had undergone RFA therapy and exhibited no recurrence of HCC 12 months thereafter. Serial changes in serum total bilirubin and albumin, prothrombin time, and Child-Pugh score were evaluated before RFA and 3, 6, 9, and 12 months thereafter. Deterioration of liver function was defined when the Child-Pugh score increased by at least 2 at 12 months after RFA therapy. We determined the factors related to aggravation of liver function after RFA therapy.ResultsLiver function had deteriorated 12 months after RFA in 29 patients (28.4%). Serum albumin levels decreased significantly from before (3.7±0.1 g/dL, mean±SD) to 12 months after RFA therapy (3.3±0.1 g/dL, P=0.002). The Child-Pugh score increased significantly during the same time period (from 6.1±0.2 to 7.2±0.3, P<0.001). Pre-RFA thrombocytopenia (≤100,000/mm3) was revealed as a significant risk factor for the deterioration of liver function after RFA. However, no patients had episodes of bleeding as a complication of RFA.ConclusionsAmong the liver-function parameters, serum albumin level was markedly decreased in HCC patients over the course of 24 months after RFA therapy. A pre-RFA thrombocytopenia represents a major risk factor for the deterioration of liver function.